Molecular Therapies in Hematology

• Applicant: Professor Dr. Michael Heuser
• Subject Area: Hematology, Oncology
• Term: from 2014 to 2021
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 258445828

• Final Report Year: 2021

Final Report Abstract

No abstract available

Publications

• Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate. Leukemia, Vol. 30. 2016, pp. 1708–1715.
  Chaturvedi A., Araujo Cruz M.M., Jyotsana N., Sharma A., Goparaju R., Schwarzer S., Görlich K., Schottmann R., Struys E.A,. Jansen E.E., Rohde C., Müller-Tidow C., Geffers R., Göhring G., Ganser G., Thol F., Heuser M.
  (See online at https://doi.org/10.1038/leu.2016.71)
• Genomic Clas-sification and Prognosis in Acute Myeloid Leukemia. New England Journal of Medicine, Vol. 374. 2016, pp. 2209-2221.
  Papaemmanuil E., Gerstung M., Bullinger L., Gaidzik V., Paschka P., Potter N., Heuser M., Thol F., Bolli N., Gundem G., Van Loo P., et.al.
  (See online at https://dx.doi.org/10.1056/NEJMoa1516192)
• RNA interference efficiently targets human leu-kemia driven by a fusion oncogene in vivo. Leukemia, Vol. 32. 2017, pp. 224-226.
  Jyotsana N, Sharma A, Chaturvedi A, Scherr M, Ku-chenbauer F, Sajti L, Barchanski A., Lindner R., Noyan F., Sühs K.W., Grote-Koska D., Brand K., Vornlocher H.P., Stanulla M., Bornhauser B., Bourquin J.P., Eder M., Thol F., Ganser A., Humphries R.K., Ramsay E., Cullis P., Heuser M.
  (See online at https://doi.org/10.1038/leu.2017.269)
• Measurable residual disease (MRD) monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood, Vol. 132. 2018, Issue 16, pp. 1703–1713.
  Thol F., Gabdoulline R., Liebich A., Klement P., Schiller J., Kandziora C., Hambach L., Stadler M., Koenecke C., Flintrop M., Pankratz M., Wichmann M., Paschka P., Döhner K., Döhner H., Ganser A., Heuser M., et al.
  (See online at https://doi.org/10.1182/blood-2018-02-829911)
• Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia. Leukemia, Vol. 34. 2020, Issue 11, pp. 2951–2963.
  Kloos A., Mintzas K., Winckler L., Gabdoulline R., Alwie Y., Jyotsana N., Kattre N., Schottmann R., Scherr M., Gupta C., Adams F.F., Schwarzer A., Heckl D., Schambach A., Imren S., Humphries R.K., Ganser A., Thol .F, Heuser M.
  (See online at https://doi.org/10.1038/s41375-020-0929-3)
• In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site. Leukemia, Vol. 34. 2020, pp. 416–426.
  Chaturvedi A., Goparaju R., Gupta C., Weder J., Klunemann T., Araujo Cruz M.M., Kloos A., Goerlich K., Schottmann R., Othman B., Struys E.A., Bahre H., Grote-Koska D., Brand K., Ganser A,. Preller M., Heuser M.
  (See online at https://doi.org/10.1038/s41375-019-0582-x)
• Meningioma 1 is indispensable for mixed lineage leukemia-rearranged acute myeloid leukemia. Haematologica, Vol. 105. 2020, No. 5, pp. 1294-1305.
  Sharma A., Jyotsana N., Gabdoulline R., Heckl D., Kuchenbauer F., Slany R.K., Ganser A., Heuser M.
  (See online at https://doi.org/10.3324/haematol.2018.211201)
• IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction-a retrospective propensity score analysis. Leukemia, Vol. 35. 2021, pp. 1301–1316.
  Kattih B., Shirvani A., Klement P., Garrido A.M., Gabdoulline R., Liebich A., Brandes M., Chaturvedi A., Seeger T., Thol F., Gohring G., Schlegelberger B., Geffers R., John D., Bavendiek U., Bauersachs J., Ganser A., Heineke J., Heuser M.
  (See online at https://doi.org/10.1038/s41375-020-01043-x)